Product Highlight - RENVELA

24 Jul 2020
Product Highlight - RENVELA

Product Characteristics:

  •  For phosphorus control in patients with Chronic Kidney Disease on dialysis.1
  •  The first non-calcium based phosphate binder the lowers progression of vascular calcification vs calcium based phosphate binder.2
  •  Renvela Powder indicated for the control of serum phosphorus in pediatric patients more than 6 years of age.3
  •  Sevelamer carbonate (Renvela) - SRP Php 56.4

References:
(1) Renvela Tablet Product Insert CCDS Version 4 Date of leaflet revision: September 2015
(2) Block GA, Raggi P, Bellasi A, Koolenga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kindey Int. 2007;71:438-441.
(3) St. Peter WL, Liu J Weinhandi E, Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomize trial using claims data. Am J, Kidney Dus. 2008-51;445-454.
(4) Mercury Drugstore Price, updated June 2020.


SANOFI-AVENTIS PHILS., INC
21st , 22nd , 23rd Flr, One World Place Corporate Offices,
32nd St Bonifacio Global City, Taguig City 1634 , Metro Manila
Website: www.sanofi.ph

Related MIMS Drugs